Isis Pharmaceuticals initiates phase 3 study of ISIS-APOCIII Rx in patients with FCS
Isis Pharmaceuticals announced initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome. The Phase 3 study of ISIS-APOCIIIRx is a randomized, double-blind, placebo-controlled, six month study in approximately 50 patients diagnosed with FCS. August 28, 2014